Pharmacokinetic, Pharmacodynamic and Pharmacogenetic of Morphine After Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of this study is to improve our knowledge on the pharmacodynamic, pharmacokinetic, and pharmacogenetic relationships of morphine administered to relief severe postoperative pain. The analysis will encompass the efficacy (acute during titration and subacute during the first 24 hours) and adverse effects of morphine. Our purpose is also to better characterize the age- and sex-related differences which probably markedly differ between the two periods (acute vs sub acute).
| Condition | Intervention |
|---|---|
|
Orthopaedic Surgery |
Drug: intravenous morphine titration |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | Assessment of the Pharmacokinetic, Pharmacodynamic, Pharmacogenetic Relationships of Morphine and Metabolites After Severe Postoperative Pain in Adults |
- To improve our knowledge on the pharmacodynamic, pharmacokinetic and pharmacogenetic relationships of morphine administered after severe postoperative pain. [ Time Frame: during the study ] [ Designated as safety issue: No ]
- - Relationships between morphine consumption, clinical events (efficacy or adverse effects) and morphine (and metabolites) blood concentrations. Immediate postoperative period (PACU) [ Time Frame: Immediate postoperative period (PACU) ] [ Designated as safety issue: No ]
- - Relationships between clinical events (pain relief, failure in pain relief, adverse effects) and genetic polymorphism. [ Time Frame: Immediate postoperative period (PACU) ] [ Designated as safety issue: No ]
- - Relationships between sub-acute clinical events and PK/PG profile. (on the wards at 24 hours after surgery) [ Time Frame: on the wards at 24 hours after surgery ] [ Designated as safety issue: No ]
- To better characterize the age- and sex-related differences which differ between acute and sub-acute periods. [ Time Frame: during the study ] [ Designated as safety issue: No ]
| Enrollment: | 438 |
| Study Start Date: | September 2006 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
all the patients included in the study received intravenous morphine in PACU and in the wards
|
Drug: intravenous morphine titration
intravenous morphine titration
Other Name: intravenous morphine titration
|
Detailed Description:
No previous study attempted to characterize the pharmacodynamic, pharmacokinetic, and pharmacogenetic relationships of morphine in the early postoperative period, whereas it is the main clinical situation for severe pain and a unique model for its study (not possible in the healthy volunteer). Indeed, intravenous titration of morphine is the first step for pain control in the postanesthesia care unit. Administration of intravenous boluses of morphine enables to obtain complete pain relief in 98% of the patients. We intend to study the effects of morphine (intravenous titration then patient-controlled intravenous administration (PCA) for 24 hours), perform dosages of plasma concentration of morphine an its main metabolites, and also study gene polymorphisms coding for main proteins involved in the pharmacokinetic and pharmacodynamic profile of morphine (hepatic metabolism, distribution and elimination, interaction with morphine receptor). Five hundred patients scheduled for major orthopedic surgery will be included in this prospective study. The main objective of this study is to improve our knowledge on the pharmacodynamic, pharmacokinetic, and pharmacogenetic relationships of morphine administered to relief severe postoperative pain. The analysis will encompass the efficacy (acute during titration and subacute during the first 24 hours) and adverse effects of morphine. Our purpose is also to better characterize the age- and sex-related differences which probably markedly differ between the two periods (acute vs subacute). We consider that this knowledge is important to confirm or not several important concepts currently used to define the appropriate analgesic regimen to control severe pain in the postoperative period.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients undergoing major orthopaedic surgery with severe postoperative pain. All the patients included in the study received intravenous morphine
Inclusion criteria :
- scheduled major orthopedic surgery
- spine, hip or knee surgery
- Body weight between 50 and 100 kg
- Caucasians
- ASA status 1 to 3
- no cognitive dysfunction
Exclusion criteria :
- allergy or contraindication to morphine
- renal impairment (Cr Cl < 30 ml/min)
- severe hepatic impairment
- surgery performed under regional anaesthesia
- preoperative treatment including strong or weak opioids
- pregnancy, patients under 18 years, addiction
Contacts and Locations| France | |
| Hopital de la Pitié Salpêtrière | |
| Paris, France, 75013 | |
| Principal Investigator: | Frederic Aubrun, MD, PhD | Assistance Publique - Hôpitaux de Paris |
More Information
No publications provided
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT00822549 History of Changes |
| Other Study ID Numbers: | AOR 05038 |
| Study First Received: | January 13, 2009 |
| Last Updated: | December 10, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Morphine titration Sub acute pain Major orthopaedic surgery Pharmacokinetics |
Pharmacodynamics Genetic polymorphism PACU Patients undergoing major scheduled orthopaedic surgery |
Additional relevant MeSH terms:
|
Morphine Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotics |
ClinicalTrials.gov processed this record on May 21, 2013